Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma

Figure 2

Progression-free-survival in metastatic renal cell carcinoma patients according to fold-increase in plasma NT-pro-BNP after two weeks of sunitinib treatment. Median PFS was 12.0 months in patients with less than 1.5 fold increases or lower or equal to baseline NT-pro-BNP levels (n = 22) and 3.9 months in patients with more than 1.5 fold increases in plasma NT-pro-BNP (n = 13) (log-rank test, p = 0.001).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us